Cargando…
Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
OBJECTIVE: Spinal muscular atrophy (SMA) is a motor neuron disease caused by low levels of survival motor neuron (SMN) protein. Prior work in models and patients has demonstrated electrophysiological and morphological defects at the neuromuscular junction (NMJ). Therapeutic development has resulted...
Autores principales: | Arnold, W David, Severyn, Steven, Zhao, Songzhu, Kline, David, Linsenmayer, Matthew, Kelly, Kristina, Tellez, Marco, Bartlett, Amy, Heintzman, Sarah, Reynolds, Jerry, Sterling, Gary, Weaver, Tristan, Rajneesh, Kiran, Burghes, Arthur H M, Kolb, Stephen J, Elsheikh, Bakri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362737/ https://www.ncbi.nlm.nih.gov/pubmed/34466806 http://dx.doi.org/10.1136/bmjno-2021-000164 |
Ejemplares similares
-
Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021) -
Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
por: Elsheikh, Bakri, et al.
Publicado: (2021) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018) -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021) -
Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)